AngioDynamics (ANGO) Misses Q3 EPS by 4c, Lowers FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity are Buyers of AngioDynamics (ANGO) on Weakness
April 10, 2015 9:55 AM EDTCanaccord Genuity analyst Jason Mills lowered his price target on AngioDynamics (NASDAQ: ANGO) to $20.00 (from $22.00) following soft Q3 results but maintained a Buy rating. The firm would be buyers on weakness.
Mills commented, "We would be buyers on weakness associated with soft FQ3 results and downward revision to guidance. On the heels of several consecutive quarters of solid execution, including expanding top-line growth and GM, a confluence of factors negatively impacted the business in F3Q, driving revenue below expectations. A few of these challenges were out of ANGOs control (negative foreign... More
AngioDynamics (ANGO) PT, Estimates Cut at Piper Jaffray Following 'Tough' Qtr
April 10, 2015 7:16 AM EDTPiper Jaffray analyst Thomas Gunderson cut estimates and his price target on Neutral-rated AngioDynamics (NASDAQ: ANGO) to $18 (from $21) following a "tough" quarter.
Gunderson commented, "ANGO reported Q3 (Feb) results that were below ours and consensus expectations; Q4 guidance was also lower than Street... More
AngioDynamics (ANGO), EmboMedics Enter Global Microspheres Licensing Agreement
April 9, 2015 4:10 PM EDTAngioDynamics (NASDAQ: ANGO) announced a worldwide licensing agreement with privately-held EmboMedics Inc., of Minneapolis, Minn., which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in Interventional Radiology, and this newly formed strategic relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the approximately $150 million addressable global embolic market.
"AngioDynamics previously helped to build the embolics market, and with worldwide rights to a margin accretive, truly novel technology, we are poised to emulate that success," said Joseph... More
